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Role of IL-16 in CD4+ T cell-mediated regulation
of relapsing multiple sclerosis
Dusanka S Skundric1*, William W Cruikshank2 and Jelena Drulovic3

Abstract
In an important article published in Nature Medicine, Liu and colleagues described a novel CD4+ FoxA1+ regulatory
T (Treg) cell population as distinct regulators of relapsing-remitting multiple sclerosis (RRMS) and experimental
autoimmune encephalomyelitis (EAE). CD4+ FoxA1+ Treg cells appear as key regulators of responsiveness to therapy
with interferon beta (IFN-β) in RRMS patients. Data indicate that CD4+FoxA1+ FOXP3− Treg cells develop within the central
nervous system (CNS), and a potential of cerebellar granule neurons (CGN) in generation of CD4+FoxA1+PD-L1hiFOXP3−
Treg cells from encephalitogenic CD4+ T cells.
A CD4 co-receptor specific ligand, IL-16, governs trafficking and biological properties of CD4+ T cells irrespective of their
activation state. Functions of IL-16, relevant to Treg cells, include expansion of CD4+CD25+ T cells in long-term cultures
with IL-2, de novo induction of FOXP-3 and migration of FOXP-3+ T cells. IL-16 is highly conserved across species including
human and mouse. CGN and neurons in hippocampus contain neuronal-IL-16 (NIL-16), splice variant of immune IL-16,
and express CD4 molecule. In a CD4-dependent manner, IL-16 supports cultured CGN survival.
Concomitant studies of RRMS lesions and corresponding MOG35–55-induced relapsing EAE in (B6 × SJL)F1 (H-2b/s) mice
discovered similar roles of IL-16 in regulation of relapsing disease. In RRMS and EAE relapse, peak levels of IL-16 and active
caspase-3 correlated with CD4+ T cell infiltration and levels of T-bet, Stat-1(Tyr701), and phosphorylated neurofilaments of
axonal cytoskeleton [NF (M + H) P], suggesting a role of locally produced IL-16 in regulation of CD4+ Th1 inflammation
and axonal damage, respectively. IL-16 was abundantly present in CD4+ T cells, followed by CD20+ B, CD8+ T, CD83+
dendritic cells, and Mac-1+ microglia. Apart from lesions, bioactive IL-16 was located in normal-appearing white matter
(NAWM) and normal-appearing grey matter (NAGM) in RRMS brain and spinal cord.
A cytokine IL-16 emerges as an important regulator of relapsing MS and EAE. Better understanding of immune
cell-neuron interactions mediated by IL-16 will foster development of more specific CD4+ T cell subset-targeted
therapies to prevent or ameliorate progression of neuroinflammation and axonal and neuronal damage. Translational
studies necessitate corresponding EAE models.
Keywords: IL-16, Multiple sclerosis, Cerebellum, CD4+ T cells, IFN-β, FoxA1, MOG, EAE, Translational, Therapy

Background
Discovery of a novel lineage of regulatory T (Treg) cells,
which are CD4+FoxA1+, as major regulators of responsiveness to IFN-β therapy in patients with relapsingremitting multiple sclerosis (RRMS), is important for
further optimization of this first in class diseasemodifying therapy (DMT). Concurrent clinical and experimental evidence support the notion that regulation
of MS progression engages distinct regulatory pathway
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carried by CD4+FoxA1+ FOXP3− Treg cells, which develop within the central nervous system (CNS) [1]. To
gain better understanding of complex cellular and molecular interactions important for disease progression,
some fundamental mechanisms underlying MS immune
pathogenesis, reinforced by this recent finding deserve
additional attention and reappraisal.
Primarily, a potential of locally inflamed CNS microenvironment to regulate plasticity of CD4+ T cell responses, by switching their functional phenotypes from
encephalitogenic to suppressive, regulatory, FoxA1 mediated, appears vital for progression of the disease [1].
Locally elaborated cytokines are critical regulators of
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types of inflammatory cell interactions and mediators of
tissue damage. In progressive inflammatory disease,
where inflammatory mediators are reoccurring, immune
cell communications are likely diverse engaging in distinctive types of relationships throughout RRMS and its
conversion into secondary progressive (SP) disease.
Additionally, effects of IFN-β therapy regulated through
CD4+ FoxA1+ Treg are shared mechanisms between
RRMS and EAE [1]. Such approach further emphasizes importance of an appropriate EAE model when studying immune regulation of MS. In order to identify ongoing
modifications in intertwined shared regulatory mechanisms, it is critical for an EAE model to resemble the
RRMS clinical course, histopathology and relevant immune
mechanisms [2,3]. Immune regulation of relapse in response to myelin oligodendrocyte glycoprotein peptide 35
to 55 (MOG35–55) is poorly studied due to a relative deficiency of relapsing EAE in mice [4]. MOG is conserved
across species. An immunodominant epitope of MOG35–55
is associated with autoimmune responses by CD4+ Th1 and
Th17 cells and/or autoantibodies in RRMS and aquaporin-4−
(AQP4−) relapsing neuromyelitis optica (NMO), respectively [5].
Finally, data from co-culture experiments prompt us to
question the nature of interactions between cerebellar
granule neurons and encephalitogenic CD4+ T cells, in
generation of CD4+FoxA1+PD-L1hiFOXP3− Tregs [1]. Demyelinating lesions in cerebellar cortex are prominent in
progressive MS [6]. Clinical signs of cerebellar dysfunction
including nystagmus and ataxic gate accompany MS [7]. In
homeostasis, hippocampal and cerebellar granule neurons
produce neuronal-IL-16 (NIL-16), a splice variant of immune IL-16, which is produced by lymphocytes, macrophages, DC, mast cells, and microglia [8-10].

Commentary
Data from RRMS tissue analysis and relapsing EAE are
concurrent in identifying a CD4+ T cell-specific chemotactic factor, IL-16, as a key regulator of progressive
CNS inflammation mediated by CD4+ Th1 cells.
In RRMS acute brain lesions, IL-16 was found in CD3+
and CD4+ T cells, followed by CD20+ B, CD8+ T and
CD83+ dendritic cells and Mac-1+ microglia. Often, IL-16
located to cell cytoplasm, less frequently to cell nucleus,
or polarized on the membrane connecting adjoining cells.
The majority of CD4+ IL-16+ cells were T-bet+ and active
caspase-3+. Increased levels of bioactive IL-16 correlated
with levels of active caspase-3, T-bet, Stat-1 (Tyr701), and
phosphorylated medium and heavy neurofilaments of
axonal cytoskeleton, [NF (M + H) P], which suggested a
role for IL-16 in regulation of CD4+ Th1 inflammation
and damage of axonal cytoskeleton, respectively. IL-16 induces migration of CD4+Tbet+ (Th1) and CD4+FOXP3+
(Treg) cells and FOXP3 de novo expression [11,12]. In the
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MS brain, highest levels of IL-16 were detected in chronic
lesions, followed by subacute and acute. Conversely, in
MS spinal cord, acute lesions contained highest levels of
IL-16. Bioactive IL-16 was also detected in normalappearing white matter (NAWM) and normal-appearing
grey matter (NAGM) in the brain and NAWM in the
spinal cord. More robust increase of IL-16 was noted in
the spinal cord compared to brain NAWM. A sharp increase of pro-IL-16 was found in NAGM in RRMS brain
[2]. Data propose regional differences in IL-16 regulation
in lesions between the brain and spinal cord and a role of
bioactive and pro-IL-16 in pathology of NAWM and
NAGM in RRMS.
Corresponding to our findings of elevated IL-16 levels
in situ, raised levels of IL-16 were detected in serum of MS
patients. Following therapy with IFN-β1a, IL-16 gene expression in peripheral blood mononuclear cells (PBMC)
and its serum levels were down regulated, suggesting IL-16
as a potential biomarker for MS [13,14]. Myelin oligodendrocyte glycoprotein (MOG)-specific CD4+Th17 exhibited more pronounced IL-16 production compared
to CD4+Th1 cells, implicating a role of IL-16 in the
regulation of Th17 responses [14].
Concurrent with RRMS findings, in relapsing-remitting
MOG35–55-induced EAE in (B6 × SJL) F1 (H-2b/s) mice,
intra-CNS production of IL-16 correlates with extensive
CD4+ T cell infiltration, accompanied by phosphorylation
of axonal cytoskeleton, which all peak during relapses and
in chronic progressive disease. IL-16 and CD4 were coprecipitated from CNS of relapsing H-2b/s mice. Data indicate that active caspase-3-mediated release of bioactive
IL-16 from infiltrating CD4+ T cells supports progression
of local inflammation by specifically enhancing trafficking
of additional CD4+ T cells [2,3,15].
As opposed to low/non-relapsing parental, B6 (H-2b),
in H-2b/s mice, immunization with MOG35–55 induces
relapsing-remitting EAE with extensive CD4+ T cell infiltration, followed by Mac-3+ macrophages, B220+ B, and CD8+
T cells. Induced autoimmune responses to MOG35–55 in
H-2b/s but not in H-2b mice result in myelin-associated
glycoprotein (MAG) predominated pattern of demyelination, which is suggestive of oligodendrocyte dysfunction
and/or damage [15,16]. A similar pattern of demyelination
was observed in the MS lesion subtype III, where profound loss of MAG serves as an indicator of a distal oligodendrogliopathy [17]. MAG-predominated demyelination,
a decrease of NF160 axonal neurofilament, and a sharp
elevation of PARPp85 suggested axonal dysfunction and irreversible apoptosis, respectively, and correlated with severe
relapsing disease in H-2b/s mice [16]. Relapsing-remitting
EAE in H-2b/s mice may provide valuable insights into
mechanisms of MAG depletion and oligodendroglial pathology initiated by autoimmune responses to MOG35–55.
Therapy with IL-16-specific antibody diminished paralysis
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and CD4+ T infiltration and abrogated demyelination and
axonal damage in relapsing EAE H-2b/s mice [18].
Studies from RRMS and corresponding MOG35–55-induced relapsing EAE in H-2b/s mice suggest a role of IL-16
in neuron-immune cell communications in lesions of gray
matter, including cerebellar and hippocampal, and in adjacent NAGM and NAWM (Skundric, unpublished). Cortical and subcortical, including hippocampal, grey matter
lesions underlie cognitive deficits observed in MS [19].
Beneficial effects of IFN-β therapy include potential
lowering of probability of disease progression from RRMS
to SP and development of Expanded Disability Status
Scale (EDSS) score [20].
Uncovering those IL-16-specific mechanisms is critical
for the development of new CD4+ T cell subset-targeted
therapies for MS and other chronic and/or progressive
inflammatory and demyelinating diseases.

Conclusion
Data from FoxA1 co-culture experiments argue for the
importance of bidirectional neuron-immune cell communications and underscore necessity for better understanding of underlying mechanisms, in particular IL-16
mediated. Future studies in this direction are required for
the development of specifically targeted therapies aimed
at preventing or ameliorating neuronal damage.
Delineating differences in mechanisms of immune
regulation between the spinal cord and brain is critical
for therapy of NMO and NMO-spectrum disorders
(NMOSD) with predominate optic nerve and spinal cord
demyelination.
Delineating molecular mechanisms enhancing migration
of encephalitogenic CD4+ cells (Th1 and Th17), and Treg
cells into the CNS throughout the disease, is essential in
the development of new therapy specific for CD4+ T cell
subsets for MS and similar inflammatory and demyelinating diseases.
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